Results 1 to 10 of about 129 (87)

CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer’s Disease

Cell Reports, 2018
Summary: Protein phosphatase 2A (PP2A) inhibition causes hyperphosphorylation of tau and APP in Alzheimer’s disease (AD). However, the mechanisms underlying the downregulation of PP2A activity in AD brain remain unclear.
Jukka Westermarck, Xiaochuan Wang
exaly   +3 more sources

Downregulation of CIP2A inhibits cancer cell proliferation and vascularization in renal clear cell carcinoma

Biomedical Papers, 2020
Background: CIP2A has been proved to play a role as an oncogene in various types of malignancies while its functionality in renal clear cell carcinoma has not been investigated.
Hui Gao, Yuqiao Li, Tao Lin, Yan Cheng, Yunbo Ma   +4 more
doaj   +1 more source

Reciprocal regulation of CIP2A and AR expression in prostate cancer cells

Discover Oncology, 2022
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein overexpressed in human malignancies, including prostate cancer (PCa). In this study, we aimed to explore the oncogenic function of CIP2A in PCa cells and its underlying mechanism. We
Hao-Wen Chuang, Jian-Hua Pan, Yi-Xuan Cai, Darius Rupa, Ting-Syuan Huang, Tzu-Chien Kuo, Chiao-Wen Lin, Chi-Wei Chen, Chia-Chin Lin, Herng-Sheng Lee, Ta-Chun Yuan   +10 more
doaj   +1 more source

CIP2A Promotes T-Cell Activation and Immune Response to Listeria monocytogenes Infection. [PDF]

PLoS ONE, 2016
The oncoprotein Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) is overexpressed in most malignancies and is an obvious candidate target protein for future cancer therapies. However, the physiological importance of CIP2A-mediated PP2A inhibition is
Christophe Côme, Anna Cvrljevic, Mohd Moin Khan, Irina Treise, Thure Adler, Juan Antonio Aguilar-Pimentel, Byron Au-Yeung, Eleonora Sittig, Teemu Daniel Laajala, Yiling Chen, Sebastian Oeder, Julia Calzada-Wack, Marion Horsch, Tero Aittokallio, Dirk H Busch, Markus W Ollert, Frauke Neff, Johannes Beckers, Valerie Gailus-Durner, Helmut Fuchs, Martin Hrabě de Angelis, Zhi Chen, Riitta Lahesmaa, Jukka Westermarck   +23 more
doaj   +1 more source

From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer

Frontiers in Genetics, 2023
Cancerous inhibitor of protein phosphatase 2A (CIP2A), initially reported as a tumor-associated antigen (known as p90), is highly expressed in most solid and hematological tumors. The interaction of CIP2A/p90, protein phosphatase 2A (PP2A), and c-Myc can
Beibei Chen, Beibei Chen, Huihui Hu, Huihui Hu, Xiaobing Chen, Xiaobing Chen   +5 more
doaj   +1 more source

CIP2A Constrains Th17 Differentiation by Modulating STAT3 Signaling

iScience, 2020
Summary: Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) is an oncogene and a potential cancer therapy target protein. Accordingly, a better understanding of the physiological function of CIP2A, especially in the context of immune cells, is a ...
Mohd Moin Khan, Ubaid Ullah, Meraj H. Khan, Lingjia Kong, Robert Moulder, Tommi Välikangas, Santosh Dilip Bhosale, Elina Komsi, Omid Rasool, Zhi Chen, Laura L. Elo, Jukka Westermarck, Riitta Lahesmaa   +12 more
doaj   +1 more source

siRNA-Mediated Silencing of CIP2A Enhances Docetaxel Activity Against PC-3 Prostate Cancer Cells [PDF]

Advanced Pharmaceutical Bulletin, 2017
Purpose: Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an identified human oncoprotein which modulates malignant cell growth. It is overexpressed in human prostate cancer and in most of the human malignancies.
Saiedeh Razi Soofiyani, Akbar Mohammad Hoseini, Ali Mohammadi, Vahid Khaze Shahgoli, Behzad Baradaran, Mohammad Saeid Hejazi   +5 more
doaj   +1 more source

CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. [PDF]

PLoS ONE, 2013
The cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncogenic factor that stabilises the c-Myc protein. CIP2A is overexpressed in several tumours, and expression levels are an independent marker for long-term outcome.
Armin Wiegering, Christina Pfann, Friedrich Wilhelm Uthe, Christoph Otto, Lukas Rycak, Uwe Mäder, Martin Gasser, Anna-Maria Waaga-Gasser, Martin Eilers, Christoph-Thomas Germer   +9 more
doaj   +1 more source

ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells.

PLoS ONE, 2011
EGFR-MEK-ERK signaling pathway has an established role in promoting malignant growth and disease progression in human cancers. Therefore identification of transcriptional targets mediating the oncogenic effects of the EGFR-MEK-ERK pathway would be highly
Anchit Khanna, Juha Okkeri, Turker Bilgen, Timo Tiirikka, Mauno Vihinen, Tapio Visakorpi, Jukka Westermarck   +6 more
doaj   +1 more source

CIP2A mediates fibronectin-induced bladder cancer cell proliferation by stabilizing β-catenin

Journal of Experimental & Clinical Cancer Research, 2017
Background Fibronectin (FN) is associated with tumorigenesis and progression in bladder cancer, however, the underlying mechanisms causing this remain largely unknown.
Fengbin Gao, Tianyuan Xu, Xianjin Wang, Shan Zhong, Shanwen Chen, Minguang Zhang, Xiaohua Zhang, Yifan Shen, Xiaojing Wang, Chen Xu, Zhoujun Shen   +10 more
doaj   +1 more source